Get the Stockscreener App
3.94
1.03%
0.04
Pre-market:
4.05
0.11
+2.79%
Protara Therapeutics Inc stock is traded at $3.94, with a volume of 494.48K.
It is up +1.03% in the last 24 hours and down -22.75% over the past month.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
See More
Previous Close:
$3.90
Open:
$3.93
24h Volume:
494.48K
Relative Volume:
0.68
Market Cap:
$221.44M
Revenue:
-
Net Income/Loss:
$-57.44M
P/E Ratio:
-2.9489
EPS:
-1.3361
Net Cash Flow:
$-56.46M
1W Performance:
-2.48%
1M Performance:
-22.75%
6M Performance:
-28.36%
1Y Performance:
+25.48%
1-Day Range:
$3.92
$4.105
1-Week Range:
$3.615
$4.185
52-Week Range:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.94 | 221.44M | 0 | -57.44M | -56.46M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Initiated | JP Morgan | Overweight |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Protara Therapeutics Stockholders Approve Governance and Share Increases - TipRanks
Protara Therapeutics (TARA) investors approve share increase and pay items - Stock Titan
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
Protara Therapeutics (TARA) Dips 3.8% as Stock Nears Key Support LevelTrend Following Picks - newsline.com
Protara Therapeutics Q1 2026 Earnings: EPS Beat Driven by Expense Management, Stock SlipsStrong Earnings Momentum - newsline.com
Protara Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SentimentProduct Revenue Analysis - newsline.com
Protara Therapeutics (NASDAQ: TARA) CCO has 6,008 RSU shares withheld for taxes - Stock Titan
Protara Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
What's Driving Protara's Recent Surge - Kavout
Protara Therapeutics (TARA) Dips 2% as Stock Hovers Near SupportCharm Flow - The Legal Advocate
Protara Therapeuticsenters sales agreement with TD Cowen for common stock offering - marketscreener.com
Protara Therapeutics (NASDAQ: TARA) secures $100M ATM sales agreement with TD Cowen - Stock Titan
Protara Therapeutics (TARA) Q1 2026 Earnings: Narrower Loss Beats Street Estimates on Cost Management - The Legal Advocate
TARA: TARA-002 shows strong efficacy and regulatory momentum in LM and NMIBC, with key H2 catalysts - TradingView
TARA: TARA-002 shows strong efficacy and regulatory momentum in LM and NMIBC, targeting broad markets - TradingView
Protara’s cell therapy shows treatment durability in mid-stage NMIBC study - MSN
[EFFECT] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara Therapeutics Q1 2026 Earnings: EPS Beat Despite No Revenue; Stock DeclinesTangible Book Value - newsline.com
Protara Therapeutics Q1 2026 Earnings: EPS Beats Estimates Amid Continued Pipeline ProgressEstimate Accuracy - newsline.com
Piper Sandler initiates coverage of Protara Therapeutics (TARA) with overweight recommendation - MSN
Protara Therapeutics Inc stock (US87612E1064): analyst optimism contrasts with volatile share price - AD HOC NEWS
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $24 to $28 - Moomoo
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer - The Globe and Mail
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Elevance Health (ELV) - The Globe and Mail
Piper Sandler Maintains Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $24 - Moomoo
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Protara Therapeutics (TARA) - The Globe and Mail
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic MalformationsSlideshow (NASDAQ:TARA) 2026-05-20 - Seeking Alpha
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $25 to $27 - Moomoo
TARA Maintained by Oppenheimer -- Price Target Raised to $28.00 - GuruFocus
Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating - Moomoo
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus
Cantor Fitzgerald reiterates Protara Therapeutics stock rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Protara Therapeutics stock rating - Investing.com
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - The Manila Times
H.C. Wainwright reiterates Protara stock rating citing LM data By Investing.com - Investing.com Canada
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Raises Target Price to $25 - Moomoo
TARA: TARA-002 delivers strong, durable efficacy and safety for lymphatic malformations, targeting FDA approval - TradingView
J.P. Morgan Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Protara Therapeutics reports 55% complete response rate in bladder cancer study - MSN
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 - Sahm
Protara Therapeutics (TARA) Stock Analysis: Falls -0.65%, Watching $4.34 2026-05-19Long Short Pair - newsline.com
protara therapeutics, inc. Earnings dates - RTTNews
Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program - Quiver Quantitative
Protara Therapeutics to Host Virtual Investor Webinar to - GlobeNewswire
Protara Therapeutics Inc stock (US87612E1064): bladder cancer data put small-cap biotech in focus - AD HOC NEWS
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Protara Therapeutics (TARA) Unveils Promising Phase 2 Trial Resu - GuruFocus
Janus Henderson (TARA) disclosed 5.21M-share, 9.6% stake in Protara - Stock Titan
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study - Benzinga
Oppenheimer Keeps Their Buy Rating on Protara Therapeutics (TARA) - The Globe and Mail
Protara reports 12-month data for bladder cancer therapy By Investing.com - Investing.com South Africa
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):